This item is non-discoverable
AGUILERA SANHUEZA, XIMENA PAZ
Preferred name
AGUILERA SANHUEZA, XIMENA PAZ
Main Affiliation
Email
xaguilera@udd.cl
ORCID
0000-0002-8153-6733
Scopus Author ID
6603011009
49 results
Now showing 1 - 10 of 49
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Barriers and facilitators to antenatal care in adolescents: Results of a qualitative study in Chile(2013); ; 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 3Scopus© Citations 5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Modeling the Spread of Tuberculosis in Semiclosed Communities(2013); 1Scopus© Citations 17 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 18Scopus© Citations 8 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile(2022); ; ; <jats:p>Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access.</jats:p>6Scopus© Citations 13 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Exposure to tobacco impressions during prime-time TV
among Chilean minors by sex and socioeconomic status(2022); ; ; 18 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hospitalización domiciliaria: aspectos conceptuales y su aplicación en el Hospital Padre Hurtado, Santiago de Chile. Descripción de funcionamiento y su rol durante la primera ola de la pandemia COVID-19(2022); 21Scopus© Citations 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Knowledge, attitudes, and practices regarding hantavirus disease and acceptance of a vaccine trial in rural communities of southern Chile(2017); 1Scopus© Citations 15 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, SARS-CoV-2 infectivity and antigenic evasion: spotlight on isolated Omicron sub-lineages(2024)5Scopus© Citations 4